

MAY 05 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Catherine Anne ABBOTT, et al.)	
)	
Serial No.	10/825,632)	FCSB-100-Div. 1
)	
Filed:	April 15, 2004)	Group Art Unit: 1646
)	
For:	DIPEPTIDYL PEPTIDASES)	
)	
Examiner:	Sheridan Swope, Ph.D.)	

INFORMATION DISCLOSURE STATEMENT**VIA FACSIMILE TO: Fax No. 571-273-8300**

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, §1.97 and §1.98, documents that may be material to the examination of this application are listed on the attached forms PTO/SB/08A and PTO/SB/08B. In accordance with the waiver of Rule 1.98(a)(2)(I), (OG Notice of August 5, 2003), copies of U.S. patent documents are not enclosed.

The cited documents disclose numerous specific features. There has been no attempt to enumerate each and every feature disclosed by each document, however. The Examiner is requested to review these documents and to determine the extent of the materiality of the document disclosures, if any, with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Serial No. 10/825,632

-2-


Applicants reserve the right to later set forth how the claimed invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, as well as documents that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,


Dated: May 5, 2006

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180

By 
Talivaldis Cepuritis (Reg. No. 20,818)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and the accompanying references referred to therein are being transmitted by facsimile transmission to Fax No. 571-273-8300 on May 5, 2006.


Talivaldis Cepuritis (Reg. No. 20,818)

MAY 05 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
No collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/825,632
Filing Date	April 15, 2004
First Named Inventor	ABBOTT, et al.
Art Unit	1646
Examiner Name	Sheridan Swope
Attorney Docket Number	FCSB-100 Div. 1

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Times will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

MAY 05 2006

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/825,632
		Filing Date	April 15, 2004
		First Named Inventor	ABBOTT, et al.
		Art Unit	1646
		Examiner Name	Sheridan Swope
Sheet 2	of 2	Attorney Docket Number	FCSB-100-Div. 1

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		QI, et al., Human DPPIV Related Serine Protease DPRP-1, from WO 200231134, April 18, 2002, Seq.ABG61591, Alignment with SEQ ID NO: 1.	
		KAWAKAMI, et al., EMBL Acc# AK000290 alignment with SEQ ID NO: 1, February 22, 2000.	
		Database EMBL 'Online! retrieved from EMBL Database Accession No. AA417787; XP002266787 (Abstract).	
		Database EMBL 'Online! retrieved from EMBL Database Accession No. AA278625; XP002266788 (Abstract).	
		Database EMBL 'Online! retrieved from EMBL Database Accession No. AA496257; XP002266789 (Abstract).	
		UNIPROT Accession No. O75273 from the UNIPROT Protein Database	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.